Myopia Treatment Market Forecasts to 2030 - Global Analysis By Type (Simple Myopia,High Myopia, Pathological Myopia and Other Types), Treatment, Route of Administration, Age Group, End User and By Geography

According to Stratistics MRC, the Global Myopia Treatment Market is accounted for $12523.10 billion in 2024 and is expected to reach $22661.58 billion by 2030 growing at a CAGR of 10.39% during the forecast period. Myopia treatment refers to various methods used to slow, stop, or correct nearsightedness, a condition where distant objects appear blurry while close objects remain clear. Treatment options include prescription eyeglasses or contact lenses, orthokeratology (corneal reshaping lenses), atropine eye drops, and refractive surgeries like LASIK or PRK. Myopia management strategies, especially in children, aim to slow progression using lifestyle changes such as increased outdoor activities and reduced screen time. Advances in myopia control focus on innovative lenses and pharmaceutical approaches to prevent high myopia-related complications like retinal detachment and glaucoma.

Market Dynamics:

Driver:

Growing awareness and diagnosis

Early case detection is being achieved by expanded screening initiatives in workplaces and schools. Improvements in diagnostic technologies allow for accurate identification and prompt action. Growing knowledge of available treatments, such as atropine drops, orthokeratology, and corrective glasses, accelerates market expansion. Concerns about digital eye strain and public health initiatives further motivate people to give eye care first priority. As a consequence of the growing need for efficient solutions, the market for myopia treatments is growing quickly.

Restraint:

Limited availability of specialized treatments

Many cutting-edge therapies, such atropine eye drops and orthokeratology, are not generally available, particularly in rural regions. Patients become dependent on traditional eyeglasses and contact lenses as a result of this limitation in access to efficient remedies. The broad use of specialised therapies is further discouraged by high prices and a lack of experience. Additionally, market progress is slowed in emerging nations by a lack of infrastructure and knowledge. Consequently, even if the frequency of myopia is rising, the market's potential for expansion is still limited.

Opportunity:

Telemedicine and digital eye health solutions

Remote consultations lower the risk of developing severe myopia by facilitating early identification and prompt correction. When prescribing remedial therapies like orthokeratology and atropine drops, AI-powered diagnostic tools improve accuracy and efficiency. Programs for digital vision therapy offer individualised treatment regimens that enhance patient compliance and results. Proactive management is encouraged by the increased use of wearable technology and smartphones, which provide ongoing monitoring of eye health. These developments thereby increase market growth by improving the effectiveness and convenience of myopia therapy.

Threat:

Post-treatment complications

The side effects of LASIK or ortho-k lenses, including as dry eyes, glare, halos, and regression of vision correction, discourage people from pursuing these procedures. Serious side effects, such as corneal infections and retinal detachment, make patients and medical professionals even more concerned about patient safety. Costs are raised by the requirement for corrective surgery and follow-up therapies, which limits access to myopia therapy. Word-of-mouth and unfavourable patient experiences deter potential patients from seeking care. Consequently, the industry is confronted with reduced growth potential and slower adoption rates.

Covid-19 Impact

The COVID-19 pandemic significantly impacted the myopia treatment market, disrupting supply chains and delaying elective eye care procedures. Lockdowns and increased screen time due to remote work and online learning contributed to rising myopia cases, especially among children. While initial restrictions led to reduced patient visits and treatment adoption, demand surged post-pandemic as awareness of eye health grew. Advancements in orthokeratology, atropine eye drops, and innovative corrective lenses gained traction, driving market recovery and long-term growth in myopia management solutions.

The simple myopia segment is expected to be the largest during the forecast period

The simple myopia segment is expected to account for the largest market share during the forecast period, due to its rising global prevalence, especially among children and young adults. Increasing screen time and reduced outdoor activities contribute to the growing cases, fuelling demand for corrective solutions. Advancements in optical treatments, such as specialized contact lenses and orthokeratology, further boost market growth. Additionally, the availability of pharmacological interventions like low-dose atropine expands treatment options.

The parenteral segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the parenteral segment is predicted to witness the highest growth rate by offering advanced drug delivery methods that ensure rapid and effective therapeutic outcomes. Injectable treatments, such as atropine injections, provide sustained drug release, reducing progression in high-risk myopic patients. This segment benefits from technological advancements in biologics and gene therapy, enhancing precision and efficacy. Increased R&D investments and regulatory approvals for novel injectables further drive market growth. The rising prevalence of severe myopia cases boosts demand for parenteral interventions, reinforcing their market impact.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to rising cases of myopia and growing awareness of early intervention. Advanced treatments like orthokeratology, atropine eye drops, and laser surgery are gaining traction. The presence of key players, technological advancements, and supportive healthcare policies drive market growth. The demand for pediatric myopia management is increasing, with innovations in contact lenses and surgical options. The U.S. dominates the market, followed by Canada, due to strong healthcare infrastructure and research investments.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to increasing screen time and growing awareness about eye health. Countries like China, Japan, and South Korea are at the forefront, driven by advanced eye care solutions and government initiatives. Innovations in orthokeratology lenses, atropine eye drops, and surgical procedures fuel market expansion. Additionally, rising disposable incomes and the availability of specialized treatments contribute to demand. The market is poised for continuous growth with ongoing technological advancements.

Key players in the market

Some of the key players profiled in the Myopia Treatment Market include Johnson & Johnson Vision, Novartis AG, CooperVision, Bausch & Lomb, EssilorLuxottica, Carl Zeiss Meditec AG, Alcon, Hoya Corporation, Nidek Co., Ltd., STAAR Surgical Company, Ziemer Ophthalmic Systems AG, Menicon Co., Ltd., SynergEyes, Inc., Abbott Medical Optics Inc., Visioneering Technologies, Inc., Lumenis Ltd., NeoVista, Inc. and Presbia PLC.

Key Developments:

In December 2024, EssilorLuxottica agreed to acquire Espansione Group, an Italy-based company specializing in non-invasive medical devices for diagnosing and treating dry-eye, ocular surface, and retinal diseases. This acquisition aims to strengthen EssilorLuxottica's position in the med-tech sector and enhance its portfolio of vision care solutions.

In July 2024, EssilorLuxottica announced the acquisition of a majority stake in Heidelberg Engineering, a German company specializing in ophthalmic diagnostic instruments. This acquisition is expected to bolster EssilorLuxottica's capabilities in providing comprehensive diagnostic and surgical solutions, supporting early diagnosis and treatment of eye conditions, including myopia.

In May 2023, EssilorLuxottica partnered with Chalhoub Group to form a joint venture focused on expanding retail eyewear presence in the Gulf Cooperation Council (GCC) region. The collaboration plans to open mono-brand and multi-brand stores for iconic global brands such as Ray-Ban, Persol, Oliver Peoples, and David Clulow, aiming to enhance customer service and experiences in the region.

Types Covered:

• Simple Myopia
• High Myopia
• Pathological Myopia
• Other Types

Treatments Covered:

• Eyeglasses
• Contact Lenses
• Refractive Surgery
• LASIK
• PRK
• Ortho-K
• Other Treatments

Route of Administrations Covered:

• Oral
• Parenteral
• Other Route of Administrations

Age Groups Covered:

• Pediatric Myopia
• Adult Myopia

End Users Covered:

• Hospital Pharmacies
• Retail Pharmacies & Optical Stores
• Online Pharmacies
• Ophthalmology Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances